

**Francesco Torino**, 14.01.1965

1989 M.D. Degree *cum laude* at the Catholic University of Rome, Italy

1994 Postgraduate degree *cum laude* at the Postgraduate School of Internal Medicine, Catholic University of Rome, Italy

1994-1998: Fellowship at the Medical Oncology Division of Policlinico Universitario "A. Gemelli", Catholic University of Rome, Italy

2002 Postgraduate degree *cum laude* at the Postgraduate School of MedcOncology, University of Rome Tor Vergata, Italy

2003-2010: Senior Medical Oncologist at the Department of Medical Oncology - San Filippo Neri Hospital of Rome

#### *Current position*

Since 2010, Researcher associate at the Department of Systems Medicine - School of Medicine, University of Rome Tor Vergata, Italy; Assistant Professor of Medical Oncology, Chair of Medical Oncology - School of Medicine, University of Rome Tor Vergata, Italy

Since 2015, Senior Assistant at the Medical Oncology Division of the "Policlinico Universitario Tor Vergata", Rome.

#### *Research activity*

##### Preclinical

2004-2006: Component of Research Unit "Antitumor immunochemotherapy: antigen remodelling and silencing of Th2 immune response" (Ministero dell'Università e Ricerca Scientifica e Tecnologica, MURST).

2005-2006: Component of Research Unit "Anticancer immunochemotherapy: drug-induced upregulation of CEA expression *in vitro* and interaction between oxaliplatin and 5-fluorouracil", MURST.

2007-present: Component of Research Unit "Combined therapy with antineoplastic and immune agents: preclinical and clinical studies", MURST.

##### Clinical trials

2001-present: Co-investigator in several translational phase II-III clinical trials, mainly evaluating new drugs and combinations in solid tumors (colorectal, breast, pancreatic cancer)

##### Translational studies

1) Studies on pharmacological modulation of tumor associated antigens *in vitro* and *in vivo*.

- 2) Clinical development of targeted anticancer agents in solid tumors (phase II-III trials), particularly antiangiogenic drugs in combination with standard chemoradiotherapy of locally advanced rectal cancer;
- 3) Studies on a novel method to detect circulating tumour cells based on pharmacological induction of tumor markers.
- 4) Studies on autophagy as prognostic/predictive factor in cancer patients.
- 5) Therapeutic drug monitoring of anticancer drugs exploiting nanotechnologies.

2012-present: Principal investigator in translational trials aimed at defining the potential role of biological markers as predicting factors of endocrine toxicity induced by anticancer cytotoxic and targeted agents.

#### *Teaching activity*

2004-present: Professor of Medical Oncology, Postgraduate School of Medical Oncology, of Radiotherapy, of Urology, of Gynecology, and of Emergency Medicine of the University of Rome Tor Vergata.

2010-present: Assistant Professor of Medical Oncology University of Rome Tor Vergata and Professor of Oncology at the Nursery School and at the Podiatrist School, University of Rome Tor Vergata.

2013-present: Professor of Medical Oncology at Catholic University Our Lady of Good Counsel – School of Medicine, Tirana - Albania.

#### *Membership in Scientific Societies*

European Society of Medical Oncology

Italian Society of Medical Oncology

#### BIBLIOMETRIC PARAMETERS:

Author/co-author of 52 full papers in Medline-based journals and of 10 book chapters. H-index: 16. Citation number (WoS): 792; Sum of times cited without self-citations: 759.

1. Franzese O, **Torino F**, Fuggetta MP, Aquino A, Roselli M, Bonmassar E, Giuliani A and D'Atri S. Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. *Oncotarget* 2017, *in press*.
2. McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, **Torino F**, Fenga C, Neri LM, Marmioli S, Cocco L, Martelli AM. Effects of mutations in Wnt/ $\beta$ -catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. *Biochim Biophys Acta*. 2016 Dec;1863(12):2942-2976.
3. Paragliola RM, Prete A, Papi G, **Torino F**, Corsello A, Pontecorvi A, Corsello SM. Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors. *Drug Des Devel Ther*. 2016; 10:3459-3470.

4. Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, **Torino F**, Signorelli SS, Montella M, Libra M. Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. *Oncotarget*. 2016 Sep 1. doi: 10.18632/oncotarget.11805.
5. Paragliola RM, **Torino F**, Papi G, Locantore P, Pontecorvi A, Corsello SM. Mouse models of medullary thyroid cancer and developing new targeted therapies. *Expert Opin Drug Discov*. 2016; 11(10):917-9.
6. Strigari L, Pinnarò P, Carlini P, **Torino F**, Strolin S, Minosse S, Sanguineti G, Benassi M. Efficacy and mucosal toxicity of concomitant chemo-radiotherapy in patients with locally-advanced squamous cell carcinoma of the head-and-neck in the light of a novel mathematical model. *Crit Rev Oncol Hematol*. 2016 Jun;102:101-10.
7. **Torino F**, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. *Curr Opin Oncol*. 2016 Jul;28(4):278-87.
8. Falasca L, **Torino F**, Marconi M, Costantini M, Pompeo V, Sentinelli S, De Salvo L, Patrizio M, Padula C, Gallucci M, Piacentini M, Malorni W. AMBRA1 and SQSTM1 expression pattern in prostate cancer. Apoptosis. 2015 Dec;20(12):1577-86.
9. Barnabei A, Strigari L, Marchetti P, Sini V, De Vecchis L, Corsello SM, **Torino F**. Predicting Ovarian Activity in Women Affected by Early Breast Cancer: A Meta-Analysis-Based Nomogram. *Oncologist*. 2015;20(10):1111-8. doi: 10.1634/theoncologist.2015-0183. Scopus: 2-s2.0-84943249191. WOS: 000366041500003.
10. Paragliola RM, Capoluongo E, **Torino F**, Minucci A, Canu G, Prete A, Pontecorvi A, Corsello SM. A rare case of juvenile hypertension: coexistence of type 2 multiple endocrine neoplasia -related bilateral pheochromocytoma and reninoma in a young patient with ACE gene polymorphism. *BMC Endocr Disord*. 2015 Jun 18;15:30.
11. Prandi C, Garrino L, Mastromarino P, **Torino F**, Vellone E, Peruselli C, Alvaro R. Barriers in the management of cancer-related pain and strategies to overcome them: findings of a qualitative research involving physicians and nurses in Italy. *Ann Ist Super Sanita*. 2015;51(1):71-8.
12. Appetecchia M, Barnabei A, Pompeo V, Sentinelli S, Baldelli R, Corsello SM, **Torino F**. Testicular and inguinal lymph node metastases of medullary thyroid cancer: a case report and review of the literature. *BMC Endocr Disord*. 2014;14:84. doi: 10.1186/1472-6823-14-84.
13. Paragliola RM, **Torino F**, Senes P, Castellino L, Salutari V, Pontecorvi A, Scambia G, Corsello SM. "Occult" ovarian Leydig cell tumor: when laboratory tells more than imaging. *Endocrine*. 2014 Jun;46(2):351-4.
14. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, **Torino F**, Corsello SM, Lenzi A, Appetecchia M. *Front Endocrinol (Lausanne)*. 2014 Feb 7;5:7.
15. Simeone S, Savini S, Torino F, Vellone E, Alvaro R. Mutuality in caregiving: a literature review. *Prof Inferm*. 2014 Jul-Sep;67(3):155-65.
16. Limardi S, Rocco G, Stievano A, Vellone E, Valle A, **Torino F**, Alvaro R. Cultural adaptation and linguistic validation of the Family Decision Making Self Efficacy Scale (FDMSES). *Ann Ig*. 2014 Jul-Aug;26(4):355-66.
17. **Torino F**, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. *Eur J Endocrinol*. 2013;169(6):R153-64.

18. **Torino F**, Barnabei A, De Vecchis L, Sini V, Schittulli F, Marchetti P, Corsello SM. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. *Crit Rev Oncol Hematol*. 2014 Jan;89(1):27-42.
19. Corsello SM, Salvatori R, Barnabei A, De Vecchis L, Marchetti P, **Torino F**. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). *Cancer Chemother Pharmacol*. 2013 Aug;72(2):489-90.
20. **Torino F**, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM. Thyroid dysfunction as an unintended side effect of anticancer drugs. *Thyroid*. 2013 Nov;23(11):1345-66.
21. **Torino F**, Sarmiento R, Gasparini G. The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer. *Crit Rev Oncol Hematol*. 2013 Sep;87(3):283-305.
22. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, **Torino F**. Endocrine side effects induced by immune checkpoint inhibitors. *J Clin Endocrinol Metab*. 2013 Apr;98(4):1361-75.
23. **Torino F**, Bonmassar E, Bonmassar L, De Vecchis L, Barnabei A, Zuppi C, Capoluongo E, Aquino A. Circulating tumor cells in colorectal cancer patients. *Cancer Treat Rev*. 2013;39(7):759-72.
24. **Torino F**, Barnabei A, De Vecchis L, Salvatori R, Corsello SM. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. *Oncologist*. 2012;17(4):525-35.
25. **Torino F**, Barnabei A, De Vecchis L, Appetecchia M, Strigari L, Corsello SM. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer. *Endocr Relat Cancer*. 2012 Apr 10;19(2):R21-33.
26. Gasparini G, **Torino F**, Ueno T, Cascinu S, Troiani T, Ballestrero A, Berardi R, Shishido J, Yoshizawa A, Mori Y, Nagayama S, Morosini P, Toi M. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. *Angiogenesis*. 2012 Mar;15(1):141-50.
27. Bonmassar L, Fossile E, Scoppola A, Graziani G, Prete SP, Formica V, Cappelletti D, De Vecchis L, Cardillo A, Concolino F, D'Atri S, Balduzzi A, **Torino F**, Caporaso P, Greiner JW, Bonmassar E, Roselli M, Aquino A. Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. *Anticancer Res*. 2010 Nov;30(11):4721-30.
28. **Torino F**, Paragliola RM, Barnabei A, Corsello SM. Medullary thyroid cancer: a promising model for targeted therapy. *Curr Mol Med*. 2010 Oct;10(7):608-25.
29. **Torino F**, Corsello SM, Longo R, Barnabei A, Gasparini G. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors? *Thyroid*. 2009 May;19(5):539-40.
30. **Torino F**, Corsello SM, Longo R, Barnabei A, Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. *Nat Rev Clin Oncol*. 2009 Apr;6(4):219-28.
31. Bazuro GE, **Torino F**, Gasparini G, Capurso L. Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all? *Minerva Gastroenterol Dietol*. 2008 Dec;54(4):429-44.
32. Prete SP, Turriziani M, Massara MC, De Rossi A, Correale P, De Vecchis L, **Torino F**, Bonmassar L, Aquino A. Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. *J Exp Clin Cancer Res*. 2008 May 19;27:5.
33. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, **Torino F**, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. *Pharmacol Res*. 2007 Oct;56(4):275-87.
34. Longo R, **Torino F**, Castellana M, Amici S, Veri A, Cacciamani F, Gasparini G, Lanzi G. Skin acrometastases in squamous cell carcinoma of the tongue. *J Clin Oncol*. 2007 Jul 1;25(19):2847-8.

35. Longo R, **Torino F**, Gasparini G. Targeted therapy of breast cancer. *Curr Pharm Des.* 2007;13(5):497-517. Scopus: 2-s2.0-33947610173. WOS: 000245201000006.
36. De Rossi A, Rossi L, Laudisi A, Sini V, Toppo L, Marchesi F, Tortorelli G, Leti M, Turriziani M, Aquino A, Bonmassar E, De Vecchis L, **Torino F**. Focus on Fotemustine. *J Exp Clin Cancer Res.* 2006 Dec;25(4):461-8.
37. Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, **Torino F**, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. *Breast Cancer Res Treat.* 2007 Mar;101(3):355-65.
38. Morabito A, Longo R, Gattuso D, Carillio G, Massaccesi C, Mariani L, Bonginelli P, Amici S, De Sio L, Fanelli M, **Torino F**, Bonsignori M, Gasparini G. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. *Oncol Rep.* 2006 Aug;16(2):393-8.
39. Correale P, Cusi MG, Micheli L, Nencini C, Del Vecchio MT, **Torino F**, Aquino A, Bonmassar E, Francini G, Giorgi G. Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. *Invest New Drugs.* 2006 Mar;24(2):99-110. S
40. Gasparini G, Longo R, **Torino F**, Gattuso D, Morabito A, Toffoli G. Is tailored therapy feasible in oncology? *Crit Rev Oncol Hematol.* 2006 Jan;57(1):79-101.
41. Gasparini G, Gattuso D, Morabito A, Longo R, **Torino F**, Sarmiento R, Vitale S, Gamucci T, Mariani L. Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. *Oncologist.* 2005 Oct;10(9):710-7.
42. Longo R, **Torino F**, Morabito A, Amici S, Gattuso D, Manente L, Gasparini G. Failure of a cetuximab/bevacizumab schedule in a patient with metastatic desmoplastic small round-cell tumour refractory to chemotherapy. *Clin Oncol (R Coll Radiol).* 2005 Aug;17(5):393-4.
43. Gasparini G, Longo R, **Torino F**, Barone C, Toffoli G. Tailored therapy of colorectal cancer: results, challenges and future directions. *Cancer J.* 2005 May-Jun;11(3):175-88.
44. Gasparini G, Longo R, **Torino F**, Morabito A. Therapy of breast cancer with molecular targeting agents. *Ann Oncol.* 2005 May;16 Suppl 4:iv28-36.
45. Longo R, Mocini D, Santini M, Giannantoni P, Carillio G, **Torino F**, Auriti A, Marcello R, Lanzi G, Cortese F, Gasparini G. Unusual sites of metastatic malignancy: case 1. Cardiac metastasis in hepatocellular carcinoma. *J Clin Oncol.* 2004 Dec 15;22(24):5012-4.
46. Turriziani M, Di Giacomo AM, Cardillo A, **Torino F**, Tentori L, Nasuti P, Massara MC, Roselli M, Bonmassar E, De Vecchis L. Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro. *Anticancer Res.* 2003 Nov-Dec;23(6C):4561-9.
47. Aquino A, Prete SP, Balduzzi A, Fossile E, Formica V, **Torino F**, Bonmassar L, Di Giacomo A, Cappelletti D, Cardillo A, Graziani G. A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report. *J Chemother.* 2002 Aug;14(4):412-6.
48. Tentori L, Portarena I, **Torino F**, Scerrati M, Navarra P, Graziani G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. *Glia.* 2002 Oct;40(1):44-54.
49. Pietrantonio F, Moriconi L, **Torino F**, Romano A, Gargovich A. Unusual reaction to chlorambucil: a case report. *Cancer Lett.* 1990 Nov 5;54(3):109-11.
50. S. Rossi, A. Astone, M. Agresti, A. Ferro, **F. Torino**, C.P. Lombardi, R. Bellantone, C. Barone. Primary chemotherapy in locally advanced (stage IIIb) and inflammatory breast carcinoma. A preliminary report of phase I-II study. *J of Chemotherapy* 1996, vol. 8 (suppl. 4): 254-256.

51. C. Barone, A. Astone, A. Cassano, G.M. Vitetta, M.R. Noviello, L. Moriconi, **F. Torino**, A. Grieco. Phase II study with mitoxantrone in advanced hepatocellular carcinoma. *J. Exp. and Clin. Cancer Res.* 1991; 2: 115-117.
52. F. Pietrantonio, L. Moriconi, **F. Torino**, A. Romano, A. Gargovich. Unusual reaction to Chlorambucil: a case report. *Cancer Lett.* 1990; 54 (3):109-11.

### **Book chapters**

- D.A. Nesci, T. Polisenò, S. Aversa, A.K. Mancuso, R. Popolo, M. Annunziata, M. Aragona, P. Caiola, M. Cannas, S. Cappello, C. Casi, S. Catellani, E. Cornacchione, A. Costantini, A. De Francesco, B. Di Francesco, L. Enei, A. Ferro, F. Livio, F. Malatucca, A. Manna, V.A. Manolio, M.R. Noviello, M. Perrone, V. Pontiggia, M.P. Santucci, M. Scendoni, **F. Torino**. *“Note sulle dinamiche di un gruppo di formazione in psico-oncologia”*. In *“Metamorfosi e Cancro: studi di Psico-oncologia”*. Capitolo 11. A cura di D.A. Nesci, T. Polisenò. SEU, Roma 1997.
- R. Longo, **F. Torino**, G. Gasparini. *“Inibitori della cicloossigenasi-2”*. In *“Nuovi farmaci biomolecolari in Oncologia Medica”*. Vol. 1, Capitolo 19. A cura di V. Lorusso, S. Cinieri, D. Cova, N. Silvestris. Ed. Istituto Oncologico di Bari & Istituto Europeo di Oncologia Milano, 2005.
- R. Longo, **F. Torino**, M. Fanelli and G. Gasparini. *“Agenti antiangiogenici”*. In *“Terapia molecolare in Oncologia”*. A cura di D. Amadori e C.M. Croce. Poletto Ed. Milano, 2005.
- R. Longo, **F. Torino**, and G. Gasparini. *Prognostic and predictive significance of surrogate biomarkers of angiogenesis*. In *Cancer Drug Discovery and Development. “Antiangiogenic agents in cancer therapy”*. 2<sup>nd</sup> Ed (Chapter 29). Edited by: B.A. Teicher and L.M. Ellis. Humana Press Inc. Totowa, NJ, 2008.
- R. Longo, **F. Torino**, R. Sarmiento, F. Cacciamani, and G. Gasparini. *Antiangiogenic therapy of breast cancer: rationale and clinical results*. In *“Breast Cancer: prognosis, treatment and prevention”*. J.R. Pasqualini Ed. 2<sup>nd</sup> Ed (Chapter 13). Informa Healthcare USA Inc. New York, 2008.
- **F. Torino**, R. Sarmiento, R. Longo, and G. Gasparini. *“Therapeutic agents that inhibit angiogenesis. In “The Molecular Basis of Human Cancer”*. 2<sup>nd</sup> Ed. (Chapter 16). Humana Press Inc. Totowa, NJ, 2010.
- R. Longo, **F. Torino**, and G. Gasparini. *Combination of antiangiogenic therapy with other anticancer treatment*. In *Tumor angiogenesis – From molecular mechanism to targeted therapy*. Keck School of Medicine - University of South California, Los Angeles Ed. 2010.
- Paragliola RM, **F. Torino**, Barnabei A. and S.M. Corsello. *Genetic and Molecular Pathophysiology of Medullary Thyroid Carcinoma*. In *Thyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines (Chapter 4)*. Carpi A & Mechanick JI. Taylor & Francis Group Eds. 2011.
- **F. Torino**, Barnabei A. Paragliola RM and S.M. Corsello. *Molecular Targeted Therapies of Medullary Thyroid Carcinoma*. In *Thyroid Cancer: From Emergent Biotechnology to Clinical Practice Guidelines (Chapter 21)*. Carpi A & Mechanick JI. Taylor & Francis Group Eds. 2011
- **F. Torino**, A. Barnabei, R. Baldelli and M. Appetecchia. *Thyroid Function Abnormalities in Patients Receiving Anticancer Agents*. Neeraj Kumar Agrawal Ed. 2012 ISBN 978-953-51-0678-4.

Roma, 06.03.2017